just saw that Lexeo Therapeutics brought in Kyle Rasbach as their new CFO and honestly the timing is interesting. this guy's resume is pretty stacked - was running things at Zentalis before this, and before that he was managing like $1.8 billion in healthcare funds at Eventide. also did time at T. Rowe Price handling pharma investments, so clearly knows the biotech game.

the company's pushing hard on gene therapy for cardiovascular stuff and Alzheimer's linked to APOE4, which is a pretty specific angle. they're talking about multiple catalysts coming up in 2025, so i guess that's why they needed someone with Kyle Rasbach's background in financial planning and business development to steer things.

what's a bit odd though is the CEO was doing a ton of selling recently - like 75k shares in the past 6 months - while some hedge funds like Eventide were cutting their positions by almost 45%. but then BlackRock added over 800k shares, so mixed signals i guess?

anyway, Kyle Rasbach's got the credentials (PhD, PharmD, MBA from Citadel) and the track record, so if anyone can navigate the clinical trial uncertainties and regulatory stuff ahead, probably him. curious to see if this move actually moves the needle for $LXEO.